Stock Analysis

Top KRX Growth Companies With High Insider Ownership August 2024

Published

The South Korean market has seen a 4.0% increase over the last week, driven by a 5.6% rise in the Information Technology sector, although it has remained flat over the past year with earnings forecasted to grow by 28% annually. In this context, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business and may offer robust potential for future performance.

Top 10 Growth Companies With High Insider Ownership In South Korea

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.5%34%
Bioneer (KOSDAQ:A064550)17.5%89.7%
Fine M-TecLTD (KOSDAQ:A441270)17.2%36.4%
Global Tax Free (KOSDAQ:A204620)18.1%90.6%
Seojin SystemLtd (KOSDAQ:A178320)29.6%58.7%
INTEKPLUS (KOSDAQ:A064290)16.3%77.4%
Vuno (KOSDAQ:A338220)19.5%105%
HANA Micron (KOSDAQ:A067310)20%97.4%
UTI (KOSDAQ:A179900)33.1%122.7%
Techwing (KOSDAQ:A089030)18.7%77.8%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

EO Technics (KOSDAQ:A039030)

Simply Wall St Growth Rating: ★★★★★☆

Overview: EO Technics Co., Ltd. manufactures and supplies laser processing equipment worldwide, with a market cap of ₩1.94 billion.

Operations: Revenue from the Semiconductor Machine Division amounts to ₩305.34 billion.

Insider Ownership: 30.7%

EO Technics, a South Korean growth company with high insider ownership, is trading at 13.7% below its estimated fair value. Despite a volatile share price and lower profit margins (11%) compared to last year (16.4%), the company's earnings are forecast to grow significantly at 48.08% annually over the next three years, outpacing the market's 28.1%. Revenue is also expected to rise by 25.2% per year, surpassing market averages of 10.1%.

KOSDAQ:A039030 Earnings and Revenue Growth as at Aug 2024

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a bio company with a market cap of ₩15.54 billion, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

Operations: The company's revenue segment primarily comprises ₩121.09 million from its biotechnology division.

Insider Ownership: 26.6%

ALTEOGEN, a South Korean growth company with high insider ownership, recently received MFDS approval for Tergase®, marking its transition to a commercial-stage entity. Despite past shareholder dilution and share price volatility, the company's revenue is forecast to grow 48.7% annually, far exceeding market averages. Earnings are expected to increase by 72.95% per year, supported by high-quality earnings and significant product advantages like Tergase®'s superior purity and lower immunogenicity compared to animal-derived alternatives.

KOSDAQ:A196170 Earnings and Revenue Growth as at Aug 2024

Doosan (KOSE:A000150)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Doosan Corporation operates in heavy industry, machinery manufacturing, and apartment construction across South Korea, the United States, Asia, the Middle East, Europe, and internationally with a market cap of ₩2.40 trillion.

Operations: The company's revenue segments include Doosan Bobcat (₩9.75 billion), Doosan Energy (₩8.27 billion), Electronic BG (₩830.45 million), Doosan Fuel Cell (₩242.68 million), and Digital Innovation BU (₩281.44 million).

Insider Ownership: 38.9%

Doosan Corporation, with significant insider ownership, has shown promising signs of growth. The company reported a notable turnaround in the first quarter of 2024, achieving net income of KRW 4.98 million compared to a substantial loss the previous year. Earnings are forecast to grow by nearly 70% annually, and Doosan is expected to become profitable within three years. However, its revenue growth is projected at 2.7% per year, trailing behind the broader South Korean market's expected growth rate.

KOSE:A000150 Earnings and Revenue Growth as at Aug 2024

Taking Advantage

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com